NCT02194218View on ClinicalTrials.gov

Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2009

Conditions
Healthy
Interventions
DRUG

Nevirapine, low dose

50 mg

DRUG

Nevirapine, high dose

100 mg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY